ONCOLOGIC OUTCOMES OF STAGE IVB OR RECURRENT OR PERSISTENT CERVICAL CANCER PATIENTS WHO RECEIVED CHEMOTHERAPY IN THAILAND

被引：0
|
作者：
Ruengkhachorn, I. [1 ]
Leelaphatanadit, C. [1 ]
Hunnangkul, S. [1 ]
机构：
[1] Mahidol Univ, Fac Med, Siriraj Hosp, Obstet & Gynecol, Bangkok 10700, Thailand
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-0086
引用
收藏
页码：909 / 909
页数：1
相关论文
共 50 条
  • [1] Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy
    Ittiamornlert, Pornprom
    Ruengkhachorn, Irene
    [J]. BMC CANCER, 2019, 19 (1)
  • [2] Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy
    Pornprom Ittiamornlert
    Irene Ruengkhachorn
    [J]. BMC Cancer, 19
  • [3] Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital Thailand's Largest Tertiary Referral Center
    Ruengkhachorn, Irene
    Leelaphatanadit, Chairat
    Therasakvichya, Suwanit
    Hunnangkul, Saowalak
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (06) : 1154 - 1161
  • [4] Survival outcomes in patients with stage IVB, persistent or recurrent adenocarcinoma of the cervix treated with combination chemotherapy
    Anantawat, T.
    Rittiluechai, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Topotecan with in combination cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer
    Brave, Michael
    Dagher, Ramzi
    Farrell, Ann
    Abraham, Sophia
    Ramchandani, Roshni
    Gobburu, Jogarao
    Booth, Brian
    Jiang, Xiaoping
    Sridhara, Rajeshwari
    Justice, Robert
    Pazdur, Richard
    [J]. ONCOLOGY-NEW YORK, 2006, 20 (11): : 1401 - +
  • [6] A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
    Moore, Kathleen N.
    Herzog, Thomas J.
    Lewin, Sharyn
    Giuntoli, Robert L.
    Armstrong, Deborah K.
    Rocconi, Rodney P.
    Spannuth, Whitney A.
    Gold, Michael A.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 105 (02) : 299 - 303
  • [7] COVID-19 PREVALENCE AND ONCOLOGIC OUTCOMES OF ASYMPTOMATIC PATIENTS WITH ACTIVE CANCER WHO RECEIVED CHEMOTHERAPY
    Bilir, Cemil
    Cakir, Emre
    Gulbagci, Burcu
    Altindis, Mustafa
    Toptan, Hande
    Guclu, Ertugrul
    Demirci, Ayse
    Bayoglu, Ibrahim Vedat
    Hacibekiroglu, Ilhan
    Varim, Ceyhun
    [J]. ACTA MEDICA MEDITERRANEA, 2021, 37 (01): : 667 - 671
  • [8] Outcomes of third line chemotherapy for recurrent and persistent cervical cancer
    Manders, D. B.
    Purinton, S. C.
    Lea, J. S.
    Miller, D. S.
    Kehoe, S. M.
    Richardson, D. L.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 442 - 443
  • [9] Chemotherapy for recurrent or persistent cervical cancer
    O'Boyle, K
    [J]. CANCER INVESTIGATION, 2004, 22 (03) : 477 - 478
  • [10] Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer
    Aoki, Yoichi
    Ochiai, Kazunori
    Lim, Soyi
    Aoki, Daisuke
    Kamiura, Shoji
    Lin, Hao
    Katsumata, Noriyuki
    Cha, Soon-Da
    Kim, Jae-Hoon
    Kim, Byoung-Gie
    Hirashima, Yasuyuki
    Fujiwara, Keiichi
    Kim, Young-Tak
    Kim, Seok Mo
    Chung, Hyun Hoon
    Chang, Ting-Chang
    Kamura, Toshiharu
    Takizawa, Ken
    Takeuchi, Masahiro
    Kang, Soon-Beom
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (05) : 530 - 537
12345